Ayala Pharmaceuticals Inc (ADXS)

[fbg0316]

Or maybe it's as simple as this:

Amgen evalated the responses of the first cohort of NEO patient, and while the data was early and inconclusive, Amgen felt it pointed to significantly lower probability of success of the clincial program so decided to cuts its losses and end the partnership even after $65m of sunk costs in the program. Moreover, because Amgen did not take out any option on HOT, Amgen is not convinced ADXS' personalized or off the shelf neoantigen program has a high probability for sucess.